| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/18/2009 | US20090155287 Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| 06/18/2009 | US20090155286 Type I interferon blocking agents for prevention and treatment of psoriasis |
| 06/18/2009 | US20090155285 Tgf-beta binding antibodies |
| 06/18/2009 | US20090155284 Hgf-sf monoclonal antibody combinations |
| 06/18/2009 | US20090155283 Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 |
| 06/18/2009 | US20090155282 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 06/18/2009 | US20090155281 Methods of using antibodies that bind both bcma and taci |
| 06/18/2009 | US20090155280 Immunoglobulin Cleavage Fragments as Disease Indicators and Compositions for Detecting and Binding Such |
| 06/18/2009 | US20090155279 Pseudomonas Aeruginosa Outer Membrane Protein PA5158 |
| 06/18/2009 | US20090155278 Claudins as Markers for Early Detection, Diagnosis, Prognosis and as Targets of Therapy for Breast and Metastatic Brain or Bone Cancer |
| 06/18/2009 | US20090155277 Use of immunesuppressant receptor |
| 06/18/2009 | US20090155276 NOVEL DKKL-1 Splice Product Modulators for Cancer Diagnosis and Therapy |
| 06/18/2009 | US20090155275 Multispecific epitope binding proteins and uses thereof |
| 06/18/2009 | US20090155274 Nerve growth factor specific immunoglobulin for prevention and treatment of chronic pain, nervous system, inflammatory, skin and bone disorders; osteoarthritis |
| 06/18/2009 | US20090155273 Remedies for inflammatory bowel diseases |
| 06/18/2009 | US20090155272 Targeted pharmaceuticals and ligands |
| 06/18/2009 | US20090155271 pro-inflammatory cytokines, interleukins (IL-17A, IL-17F) |
| 06/18/2009 | US20090155270 Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza |
| 06/18/2009 | US20090155269 Mesothelin antibody protein fusions and methods of use |
| 06/18/2009 | US20090155268 Growth Factor Binding Constructs Materials and Methods |
| 06/18/2009 | US20090155267 Molecule and chimeric molecules thereof |
| 06/18/2009 | US20090155266 Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases |
| 06/18/2009 | US20090155265 Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies |
| 06/18/2009 | US20090155264 Novel composition and methods for the treatment of psoriasis |
| 06/18/2009 | US20090155263 Compositions and methods for the treatment of immune related diseases |
| 06/18/2009 | US20090155262 Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| 06/18/2009 | US20090155261 Methods and compositions for treatment and diagnosis of encephalitis or epilepsy |
| 06/18/2009 | US20090155260 Use of thymosin alpha 1 for the treatment of immunological diseases |
| 06/18/2009 | US20090155259 Extending time to disease progression or survival in cancer patients |
| 06/18/2009 | US20090155258 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 06/18/2009 | US20090155257 Immunoglobulin variants and uses thereof |
| 06/18/2009 | US20090155256 Immunotherapy Regimes Dependent On APOE Status |
| 06/18/2009 | US20090155255 Cd23 binding molecules and methods of use thereof |
| 06/18/2009 | US20090155254 Affinity Regions |
| 06/18/2009 | US20090155253 Anti-cd20 antibodies and fusion proteins therof and methods of use |
| 06/18/2009 | US20090155252 Using vascular endothelial growth factor-D (VEGF-D) specific immunoglobulin for treatment and prevention of cell proliferative and tumor disorders |
| 06/18/2009 | US20090155251 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 06/18/2009 | US20090155250 Monoclonal antibodies against orthopoxviruses |
| 06/18/2009 | US20090155249 Humanized antibody igg1 |
| 06/18/2009 | US20090155248 Antibodies to MT-SP1 serine protease |
| 06/18/2009 | US20090155247 Methods of Using Death Receptor Agonists and EGFR Inhibitors |
| 06/18/2009 | US20090155246 Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof |
| 06/18/2009 | US20090155245 Treatment for Organ Regeneration with Combination of Drug and Biologics |
| 06/18/2009 | US20090155244 Methods and compositions for poxvirus a35r protein |
| 06/18/2009 | US20090155243 Non-human model of autoimmune disease |
| 06/18/2009 | US20090155242 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response |
| 06/18/2009 | US20090155241 Prophylactic/therapeutic agent for cancer |
| 06/18/2009 | US20090155231 delivering a therapeutic agent to a solid tumor characterized by hypoxia, acidosis and hypertonicity comprising loading the therapeutic agent into sickle red blood cells; tissue targeted therapy; drug delivery |
| 06/18/2009 | US20090155230 Novel genes and markers in essential arterial hypertension |
| 06/18/2009 | US20090155212 Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| 06/18/2009 | US20090155207 Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
| 06/18/2009 | US20090155205 HUMAN ANTIBODIES THAT BIND HUMAN TNFa |
| 06/18/2009 | US20090155204 Methods for treating disorders involving monocytes |
| 06/18/2009 | US20090155203 Thrombopoietin mimetics |
| 06/18/2009 | US20090155200 Methods of promoting cartilage healing or cartilage integration |
| 06/18/2009 | US20090155176 Compositions and methods for treatment of diabetic retinopathy |
| 06/18/2009 | US20090155172 Antibodies to MAGMAS and uses thereof |
| 06/18/2009 | US20090155170 Annexin derivatives suitable for pretargeting in therapy and diagnosis |
| 06/18/2009 | US20090155165 Anti-igf-i receptor antibody |
| 06/18/2009 | CA2746551A1 Improved treatment and prophylaxis |
| 06/18/2009 | CA2708792A1 Prevention and treatment of otitis media using iga enriched milk |
| 06/18/2009 | CA2708790A1 Remedies for pemphigus containing anti fas ligand antibodies |
| 06/18/2009 | CA2708606A1 Methods of treating hematologic cancers |
| 06/18/2009 | CA2708585A1 Analysis of mixtures including proteins |
| 06/18/2009 | CA2708367A1 Vaccine directed against adenovirus serotype 14 |
| 06/18/2009 | CA2708262A1 Methods and compositions for treating liquid tumors |
| 06/18/2009 | CA2708260A1 Improved immunizing composition |
| 06/18/2009 | CA2708149A1 Combinations of therapeutic agents for treating cancer |
| 06/18/2009 | CA2708145A1 Compositions for inducing immune responses |
| 06/17/2009 | EP2070949A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 06/17/2009 | EP2070948A1 Humanized Anti-CD4 antibody with immunosuppressive properties |
| 06/17/2009 | EP2070947A1 Therapeutic and diagnostic anti-Hsp70 antibodies |
| 06/17/2009 | EP2070548A1 Diagnosis and treatment of cancer using anti-ereg antibody |
| 06/17/2009 | EP2070547A1 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor |
| 06/17/2009 | EP2070546A1 Preventives/remedies for cancer |
| 06/17/2009 | EP2070542A2 Method of extended culture of antigen-specific cyotoxic T lymphocytes |
| 06/17/2009 | EP2070530A1 Treatment of diseases associated with the use of antibiotics |
| 06/17/2009 | EP2069795A1 Synergistic treatment of cells that express epha2 and erbb2 |
| 06/17/2009 | EP2069791A1 Cellular receptor for antiproliferative factor |
| 06/17/2009 | EP2069782A1 Method for determining the quantity and quality of hybridomas as well as the use of hybridomas of suitable quality |
| 06/17/2009 | EP2069503A1 Papaya mosaic virus-based vaccines for influenza |
| 06/17/2009 | EP2069493A1 Methods and devices for the delivery of peptides into the gastric mucosa |
| 06/17/2009 | EP2069484A1 Influenza b viruses having alterations in the hemaglutinin polypeptide |
| 06/17/2009 | EP2069482A2 Influencing viral lipid constituents |
| 06/17/2009 | EP2069478A2 Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| 06/17/2009 | EP2069404A1 Humanized anti-cd100 antibodies |
| 06/17/2009 | EP2069400A1 Methods of treating rsv infections and related conditions |
| 06/17/2009 | EP2069394A1 Identification of candidate vaccine antigens from dichelobacter nodosus |
| 06/17/2009 | EP2068930A2 Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
| 06/17/2009 | EP2068929A2 Method for detecting and treating skin disorders |
| 06/17/2009 | EP2068928A2 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| 06/17/2009 | EP2068927A1 Methods of reducing eosinophil levels |
| 06/17/2009 | EP2068926A2 Il-9 in fibrotic and inflammatory disease |
| 06/17/2009 | EP2068925A2 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 06/17/2009 | EP2068924A2 Interferon alpha-induced pharmacodynamic markers |
| 06/17/2009 | EP2068923A2 Antibodies with decreased deamidation profiles |
| 06/17/2009 | EP2068922A2 Anti-il-13r alpha 1 antibodies and their uses thereof |
| 06/17/2009 | EP2068921A2 High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| 06/17/2009 | EP2068920A2 Ccr2 antagonists for treatment of fibrosis |
| 06/17/2009 | EP2068919A2 Methods of treating tendonitis in a subject by using an anti-cytokine agent |